NCT03212313View on ClinicalTrials.gov

Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant

PHASE1TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2017

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Hepatic Impairment
Interventions
DRUG

Tozadenant

Two 60 mg tablets for a total single study dose of 120 mg

Trial Locations (2)

33136

University of Miami, Miami

32809-3017

Orlando Clinical Research Center, Orlando

Sponsors

Collaborators (1)

Acorda Therapeutics
All Listed Sponsors
collaborator

Acorda Therapeutics

INDUSTRY

lead

Biotie Therapies Inc.

INDUSTRY

NCT03212313 - Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant | Biotech Hunter | Biotech Hunter